



## BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Michael E. Thase, M.D.

eRA COMMONS USER NAME (credential, e.g., agency login): Thasem

POSITION TITLE: Professor of Psychiatry

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Wright State University, Dayton, OH	B.A.	1975	Psychology
Ohio State University, Columbus, OH	M.D.	1979	Medicine
Internship, Western Psychiatric Institute and Clinic and University of Pittsburgh Medical Center		1980	Medicine and General Psychiatry
Residency, Western Psychiatric Institute and Clinic and University of Pittsburgh Medical Center		1982	General Psychiatry
Chief Resident, Western Psychiatric Institute and Clinic and University of Pittsburgh Medical Center		1983	Mood Disorders
Post-doctoral Fellowship, Western Psychiatric Institute and Clinic and University of Pittsburgh Medical Center		1984	Clinical Research

### A. Personal Statement

Michael E. Thase, M.D., is Professor of Psychiatry at the Perelman School of Medicine of the University of Pennsylvania and the Corporal Michael J Crescenz Veterans Affairs Medical Center. He is an internationally recognized leader in the assessment and treatment of mood disorders and his therapeutics research includes studies of both medications and psychotherapies. A Distinguished Life Fellow of the American Psychiatric Association, Founding Fellow of the Academy of Cognitive Therapy, and Fellow of the American College of Neuropsychopharmacology, Professor Thase is the immediate Past-President of the American Society of Clinical Psychopharmacology. Dr. Thase has published more than 1100 scientific articles and book chapters, as well as 18 books, including the award-winning *Learning Cognitive-Behavior Therapy*. For this project, Professor Thase will work closely with Dr. Goldschmeid to oversee and the conduct of the study, supervise the IV ketamine protocol, analyze and interpret data and write and oversee publication of posters, abstracts and published papers reporting the study's key findings.

### B. Positions and Honors

#### Positions and Employment

2007-Present Professor of Psychiatry, Perelman School of Medicine of the University of Pennsylvania & Philadelphia VA Medical Center, Philadelphia, PA

1998-2006 Chief, Division of Adult Academic Psychiatry, WPIC, Pittsburgh, PA

1995-2007 Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic (WPIC), Pittsburgh, PA

1988-1999 Associate Director, Clinical Research Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA

1988-1998 Medical and Research Director, Mood Disorders Module, Western Psychiatric Institute and

Clinic, Pittsburgh, PA  
 1987-1995 Associate Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, Pittsburgh, PA  
 1983-1987 Assistant Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA

**MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES**

American Medical Association 1978  
 Association for Advancement of Behavior Therapy 1980  
 American Psychiatric Association 1980  
 Pennsylvania Psychiatric Society 1980  
 Distinguished Life Fellow 2016  
 Society of Biological Psychiatry 1986  
 American College of Psychiatrists 1988  
 American Society of Clinical Psychopharmacology 1993  
 Board of Directors 2008-2021  
 Treasurer 2015-2017  
 President 2017-2019  
 Immediate Past President 2017-2019  
 American College of Neuropsychopharmacology 1995  
 Fellow 2015  
 Depression Bipolar Support Association 1990  
 Scientific Advisory Board 1995-present  
 Anxiety and Depressive Disorders Association 2004  
 Scientific Advisory Board 2014-present  
 National Network of Depression Centers 2008  
 Executive Committee 2014-2021

**HONORS**

Departmental Honors in Psychology, Wright State University 1975  
 Summa Cum Laude, Wright State University 1975  
 Landacre Research Honor Society, Ohio State University 1977  
 Alpha Omega Alpha Medical Honor Society 1978  
 AMA Rock Sleyster Scholarship for Student Achievement in Psychiatry 1978  
 Samuel Roessler Research Foundation Scholarship 1978 - 1979  
 College of Medicine Outstanding Achievement Awards  
 in Psychiatry and Preventative Medicine 1979  
 Falk Fellowship, American Psychiatric Association 1981 - 1983  
 The *Hillside Journal of Clinical Psychiatry's* Psychiatric Paper Contest, First Prize 1982  
 Laughlin Fellowship, American College of Psychiatrists 1983  
 Taylor Manor Symposium Essay Contest, First Prize 1983  
 Psychiatry and Behavioral Sciences Award, National Student Research Forum 1983  
 Sandoz Award, Western Psychiatric Institute and Clinic 1983  
 Marie Eldredge Award, American Psychiatric Association 1984  
 The American College of Psychiatrists Award for Research in Mood Disorders 2012  
 Earl Bond Award University of Pennsylvania Health System (Psychiatry) 2013  
 Alexander H. Glassman Memorial Award Columbia University (Psychiatry) 2014  
 Top Doctors, Pittsburgh Magazine 1990-2007  
 Philadelphia Magazine 2008-2021  
 Main Line Magazine 2018-2021  
 Castle Connolly Medical Ltd., America's Top Doctors 2001-2022  
 Distinguished Life Fellow, American Psychiatric Association 2015  
 Benjamin Rush Award, Philadelphia Psychiatric Society 2016  
 Martin Szuba Award, University of Pennsylvania Health System (Psychiatry) 2017  
 Alumni Achievement Award, The Ohio State University College of Medicine 2018  
 Academy of Master Clinicians, Perelman School of Medicine 2018

## C. Contributions to Science

1. Classification of and Therapeutics for Treatment Resistant Depression (TRD). In a line of research that dates to the mid-1980s, I collaborated with John Rush to propose a systematic approach to describing TRD and helped to design and oversee the Sequenced Treatment Alternatives to Relief Depression (STAR\*D) study (Rush et al., 2004), including the sub-study examining the role of CBT for antidepressant nonresponders (Thase et al., 2007). I continue to both lead and collaborate on studies of novel therapeutics for TRD, including a key role in the Phase II and Phase III studies of esketamine.
  - a) Rush, A.J. et al. Sequenced treatment alternatives to relieve depression (STAR\*D): Rationale and design. *Cont. Clin. Trials*. 25(1):119-142, 2004. (PMID: 15061154)
  - b) **Thase, M.E.**, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR\*D report. *Am. J. Psychiatry* 164(5):739-752, 2007. (PMID: 17475733)
  - c) Daly EJ, Trivedi MH, Janik A, ...**Thase, ME**, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. *JAMA Psychiatry*. 2019;76(9):893-903. doi:10.1001/jamapsychiatry.2019.1189
2. Improving Care for Depressed Veterans. Since joining the medical staff of the Corporal Michael J. Crescenz VAMC in January 2007 I have had the opportunity to build an intervention research program that has the overarching mission to improve the outcomes of the treatment received by depressed Veterans. To this end, I have helped to design, lead and/or collaborate on a number of studies that evaluate novel strategies for TRD (Mohamed et al. 2017; Yesevich et al., 2018), including a recently funded study of intranasal esketamine therapy of TRD in Veterans. In addition to playing a leading role in an innovative study evaluating a new group intervention to improve the impact of safety planning for Veterans experiencing suicidal ideation (Goodman et al., 2020), I also have mentored the projects of a number of VAMC research fellows (Hershenberg et al., 2018; Boland et al., 2020; Vargas et al., 2020; Khazanov et al., 2021). The ongoing pilot study of Dr. Khazanov, which helped to establish the feasibility of the current application, which examines the acceptability of incentive-based strategies to promote restriction of access to lethal means in suicidal Veterans.
  - a) Mohamed, S. et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. *JAMA*. 2017 Jul 11;318(2):132-145. PMID: 28697253.
  - b) Yesavage, J.A. et al. VA Cooperative Studies Program Study Team. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. *JAMA Psychiatry*. 2018;75(9):884-893. (PMID: 29955803)
  - c) Hershenberg, R., Mavandadi, S., Wright, E., **Thase, M.E.** Anhedonia in the daily lives of depressed Veterans: A pilot report on experiential avoidance as a moderator of emotional reactivity. *J Affect Disord*. 2017;208:414-417. (PMID: 27814567)
  - d) Khazanov, G.K., Xu, C., Hollon, S.D., DeRubeis, R.J., **Thase, M.E.** Adding cognitive therapy to antidepressant medications decreases suicidal ideation. *J Affect Disord*. 2021 Feb 15;281:183-191. (PMID: 33326891)
3. Using pharmacogenetic methods to improve antidepressant treatment outcomes
  - a) Greden JF, Parikh SV, Rothschild AJ, **Thase ME**, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. *J Psychiatr Res*. 2019 Apr;111:59-67
  - b) **Thase ME**, Parikh SV, Rothschild AJ, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Greden JF. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. *J Clin Psychiatry*. 2019 Oct 31;80(6):19m12910. doi: 10.4088/JCP.19m12910. PMID: 31721487.
  - c) Vest BM, Wray LO, Brady LA, **Thase ME**, Beehler GP, Chapman SR, Hull LE, Oslin DW. Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for

depression prescribing. BMC Psychiatry. 2020 Oct 28;20(1):518. doi: 10.1186/s12888-020-02919-z. PMID: 33115428; PMCID: PMC7594429.

- d) Oslin DW, Chapman S, Duvall SL, Gelernter J, Ingram EP, Kranzler HR, Lehmann LS, Lynch JA, Lynch KG, Pyne JM, Shih MC, Stone A, **Thase ME**, Wray LO. Study design and implementation of the PReCISION Medicine In MEntal health Care (PRIME Care) Trial. Contemp Clin Trials. 2021 Feb;101:106247. doi: 10.1016/j.cct.2020.106247. Epub 2020 Dec 11. PMID: 33316457.
- e) Ramsey CM, Lynch KG, **Thase ME**, Gelernter J, Kranzler HR, Pyne JM, Shih MC, Stone A; PRIME Care Executive Committee, Oslin DW. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. J Affect Disord. 2021 Mar 1;282:1272-1277 PMID: 33601706.

Complete List in My Bibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1B3PNcpA9bM5e/bibliography/47854270/public/?sort=date&direction=ascending>